FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3005226383> ?p ?o ?g. }

• W3005226383 abstract "425 Background: Clinical studies support the efficacy of immune checkpoint blockades (ICBs) in a subset of patients with metastatic gastric cancer (mGC). With the aim of identifying determinants of response to ICBs, we performed molecular characterization of tissues from 61 patients with mGC who were treated with pembrolizumab as salvage treatment in a prospective phase 2 clinical trial (NCT#02589496). Methods: Of 61 patients, 60 patients underwent pretreatment biopsy and 45 specimens were of sufficiently high quality for RNA sequencing. TMEscore, which was previously established to quantify the tumor microenvironment (TME), was used to estimated TME of pretreatment specimens. The predictive value and correlation of integrative molecular characterization were systematically explored. Results: We established a methodology (TMEscore) to evaluated the TME of GC patients, which was previously found to be a robust prognostic and predictive biomarker for patients treated with ICBs. By applying ROC curve analysis, the TMEscore was found to be a best predictive biomarker (TMEscore: AUC = 0.891; CPS: AUC = 0.830; TMB: AUC = 0.672; MSI status: AUC = 0.708; EBV status: AUC = 0.727; respectively). Moreover, TMEscore was the most significant gene signature that correlated with tumor response (TMEscore: P = 1.7 × 10 −5 ; GEPs: P = 0.00035; ImmunoScore: P = 0.29106; CD8+ T cell fraction: P = 0.00011; Immune checkpoint score: P = 0.00149; respectively). TMB was not correlated with TMEscore (Kruskal-Wallis test, P = 0.14). A higher TMEscore was significantly associated with EBV+ and high-MSI TCGA molecular subtypes (Kruskal-Wallis test, P = 0.002) which were reported to benefit from ICBs of GC. Conclusions: These findings indicate that the assessment of TMEscore via high throughput-sequencing and PCA algorithm provides a robust biomarker for the selection of GC patients who may derive greater benefit from pembrolizumab. Our data also suggest that TMEscore may be a more accurate predictive biomarker than TMB, MSI and EBV status, and this resource may help facilitate the development of precision immunotherapy. Clinical trial information: NCT#02589496." @default.
• W3005226383 created "2020-02-14" @default.
• W3005226383 creator A5006442888 @default.
• W3005226383 creator A5007648897 @default.
• W3005226383 creator A5025156575 @default.
• W3005226383 creator A5043993720 @default.
• W3005226383 creator A5064188865 @default.
• W3005226383 creator A5066349538 @default.
• W3005226383 creator A5067564208 @default.
• W3005226383 creator A5072491704 @default.
• W3005226383 creator A5078993188 @default.
• W3005226383 date "2020-02-01" @default.
• W3005226383 modified "2023-09-23" @default.
• W3005226383 title "Tumor microenvironment evaluation to predict pembrolizumab benefit of metastatic gastric cancer: Results from phase II clinical trial." @default.
• W3005226383 doi "https://doi.org/10.1200/jco.2020.38.4_suppl.425" @default.
• W3005226383 hasPublicationYear "2020" @default.
• W3005226383 type Work @default.
• W3005226383 sameAs 3005226383 @default.
• W3005226383 citedByCount "0" @default.
• W3005226383 crossrefType "journal-article" @default.
• W3005226383 hasAuthorship W3005226383A5006442888 @default.
• W3005226383 hasAuthorship W3005226383A5007648897 @default.
• W3005226383 hasAuthorship W3005226383A5025156575 @default.
• W3005226383 hasAuthorship W3005226383A5043993720 @default.
• W3005226383 hasAuthorship W3005226383A5064188865 @default.
• W3005226383 hasAuthorship W3005226383A5066349538 @default.
• W3005226383 hasAuthorship W3005226383A5067564208 @default.
• W3005226383 hasAuthorship W3005226383A5072491704 @default.
• W3005226383 hasAuthorship W3005226383A5078993188 @default.
• W3005226383 hasConcept C121608353 @default.
• W3005226383 hasConcept C126322002 @default.
• W3005226383 hasConcept C143998085 @default.
• W3005226383 hasConcept C2776107976 @default.
• W3005226383 hasConcept C2777701055 @default.
• W3005226383 hasConcept C2780057760 @default.
• W3005226383 hasConcept C2780851360 @default.
• W3005226383 hasConcept C2781197716 @default.
• W3005226383 hasConcept C55493867 @default.
• W3005226383 hasConcept C71924100 @default.
• W3005226383 hasConcept C86803240 @default.
• W3005226383 hasConceptScore W3005226383C121608353 @default.
• W3005226383 hasConceptScore W3005226383C126322002 @default.
• W3005226383 hasConceptScore W3005226383C143998085 @default.
• W3005226383 hasConceptScore W3005226383C2776107976 @default.
• W3005226383 hasConceptScore W3005226383C2777701055 @default.
• W3005226383 hasConceptScore W3005226383C2780057760 @default.
• W3005226383 hasConceptScore W3005226383C2780851360 @default.
• W3005226383 hasConceptScore W3005226383C2781197716 @default.
• W3005226383 hasConceptScore W3005226383C55493867 @default.
• W3005226383 hasConceptScore W3005226383C71924100 @default.
• W3005226383 hasConceptScore W3005226383C86803240 @default.
• W3005226383 hasLocation W30052263831 @default.
• W3005226383 hasOpenAccess W3005226383 @default.
• W3005226383 hasPrimaryLocation W30052263831 @default.
• W3005226383 hasRelatedWork W11093380 @default.
• W3005226383 hasRelatedWork W16661828 @default.
• W3005226383 hasRelatedWork W20535288 @default.
• W3005226383 hasRelatedWork W20881767 @default.
• W3005226383 hasRelatedWork W2090429 @default.
• W3005226383 hasRelatedWork W317545 @default.
• W3005226383 hasRelatedWork W4242833 @default.
• W3005226383 hasRelatedWork W6095507 @default.
• W3005226383 hasRelatedWork W6817586 @default.
• W3005226383 hasRelatedWork W828048 @default.
• W3005226383 isParatext "false" @default.
• W3005226383 isRetracted "false" @default.
• W3005226383 magId "3005226383" @default.
• W3005226383 workType "article" @default.